Guangzhou Baiyunshan Hanfang Launches Injectable Soybean Oil for DrugLoaded Emulsions

Domestically Produced, Globally Certified Solution Addresses Pharmaceutical Supply Chain Gaps

Guangzhou, China – 2026 – Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd., a leading provider of high-end pharmaceutical lipid excipients and APIs, today announced the commercial launch of its injectable soybean oil, a specialized ingredient for drug-loaded fat emulsions. This domestically developed product delivers a stable, reliable alternative to imported supplies, addressing the core pain point of consistent access to high-quality injectable-grade excipients for pharmaceutical manufacturers. As an energy supplement and pharmaceutical excipient, it is tailored for high-end injection producers, with global distribution now available through authorized channels.

Core Product Advantages & Technical Highlights

Guangzhou Baiyunshan Hanfang’s injectable soybean oil serves as a critical energy supplement and excipient for high-end injection formulations, filling the gap in domestic supply of injectable-grade materials that were previously dominated by imports. Unlike traditional alternatives, the product ensures consistent quality and stable supply, eliminating risks associated with global supply chain disruptions. Its development leverages the company’s integrated green technology platforms, including supercritical CO₂ extraction and membrane separation, to meet strict pharmaceutical purity standards.

Global Compliance & Certifications

To meet international market access requirements, the injectable soybean oil complies with strict global pharmaceutical standards and holds key certifications including EU CEP, US FDA US-DMF, Mexico Cofepris, and India DCGI. The company also holds authoritative national qualifications such as the National Engineering Research Center for Traditional Chinese Medicine Pharmaceutical Process Technology and New Drug Creation, the only national-level engineering research center in the pharmaceutical lipid field, and is recognized as a 2024 National Specialized, Sophisticated, Unique, and New "Little Giant" enterprise.

Availability & Customization Services

The injectable soybean oil is now available for global pre-order through the company’s official website (http://byshanhanfang.com/) and authorized distributors worldwide, with full-scale production and shipments underway. Beyond standard products, Guangzhou Baiyunshan Hanfang offers customized processing services tailored to specific pharmaceutical formulation needs, supporting manufacturers in developing personalized solutions for drug-loaded fat emulsions and other high-end injectables.

Executive Quote

"The launch of our injectable soybean oil marks a key step in advancing domestic substitution of high-end pharmaceutical excipients, addressing long-standing supply chain vulnerabilities in the industry," said Xu Wendong, General Manager and Deputy Director of the National Engineering Research Center at Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. "By leveraging our proprietary green technologies and global certifications, we are committed to providing reliable, cost-effective solutions that support pharmaceutical manufacturers worldwide while strengthening China’s pharmaceutical industry security."

Industry Context & Strategic Alignment

Against the backdrop of growing global demand for stable, high-quality pharmaceutical raw materials, domestic substitution has emerged as a critical priority for ensuring supply chain resilience. Guangzhou Baiyunshan Hanfang’s launch directly responds to this trend, combining advanced R&D capabilities with global compliance to position itself as a trusted partner for pharmaceutical manufacturers across 20+ countries and regions.

Future Plans

Looking ahead, Guangzhou Baiyunshan Hanfang will continue to invest in R&D for high-end pharmaceutical lipid excipients, with plans to expand its product portfolio and strengthen global distribution networks. The company aims to achieve double-digit growth in revenue and profit in 2026, further solidifying its position as a leader in the global pharmaceutical raw materials market.

About Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd.

Established in 1998, Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. is a state-owned enterprise under the Guangzhou Pharmaceutical Holdings (GPHL) Group, specializing in APIs, pharmaceutical lipid excipients, health products, and technical services. With core R&D centers in Guangzhou and Zhuhai Hengqin, and a single production base in Conghua, Guangzhou, the company holds over 240 patents and serves more than 1,000 clients worldwide, including global pharmaceutical leaders like B. Braun and AstraZeneca. Its mission is to advance technological self-reliance, break "bottleneck" technologies, and safeguard pharmaceutical industry chain security.

Contact Information

Company: Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd.
Official Website: http://byshanhanfang.com/

© 2026 Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. All Rights Reserved.